ATE209490T1 - Substanz p antagonisten zur behandlung von erbrechen - Google Patents

Substanz p antagonisten zur behandlung von erbrechen

Info

Publication number
ATE209490T1
ATE209490T1 AT94303467T AT94303467T ATE209490T1 AT E209490 T1 ATE209490 T1 AT E209490T1 AT 94303467 T AT94303467 T AT 94303467T AT 94303467 T AT94303467 T AT 94303467T AT E209490 T1 ATE209490 T1 AT E209490T1
Authority
AT
Austria
Prior art keywords
vomiting
antagonists
substance
treatment
derivatives
Prior art date
Application number
AT94303467T
Other languages
English (en)
Inventor
Manoj C Desai
Iii John A Lowe
John W Watson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE209490T1 publication Critical patent/ATE209490T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT94303467T 1993-06-04 1994-05-16 Substanz p antagonisten zur behandlung von erbrechen ATE209490T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/072,629 US5393762A (en) 1993-06-04 1993-06-04 Pharmaceutical agents for treatment of emesis

Publications (1)

Publication Number Publication Date
ATE209490T1 true ATE209490T1 (de) 2001-12-15

Family

ID=22108825

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94303467T ATE209490T1 (de) 1993-06-04 1994-05-16 Substanz p antagonisten zur behandlung von erbrechen

Country Status (19)

Country Link
US (1) US5393762A (de)
EP (1) EP0627221B1 (de)
JP (1) JP2671972B2 (de)
KR (1) KR100190729B1 (de)
CN (1) CN1100535C (de)
AT (1) ATE209490T1 (de)
AU (1) AU666077B2 (de)
CA (1) CA2124990C (de)
DE (1) DE69429208T2 (de)
DK (1) DK0627221T3 (de)
ES (1) ES2164088T3 (de)
HU (1) HU222243B1 (de)
IL (1) IL109802A (de)
MY (1) MY115310A (de)
NZ (1) NZ260674A (de)
PT (1) PT627221E (de)
RU (1) RU2135179C1 (de)
TW (1) TW318791B (de)
ZA (1) ZA943896B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
JPH07110850B2 (ja) * 1991-06-20 1995-11-29 フアイザー・インコーポレイテツド 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
EP0533280B2 (de) 1991-09-20 2004-12-01 Glaxo Group Limited Neue medizinische Indikation für Tachykinin-Antagonisten
US6048859A (en) 1992-06-29 2000-04-11 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
ATE166650T1 (de) * 1993-03-04 1998-06-15 Pfizer Spiroazacyclischderivate als substanz p antagonisten
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
US5576317A (en) * 1994-12-09 1996-11-19 Pfizer Inc. NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis
WO1996030367A1 (fr) * 1995-03-27 1996-10-03 Hisamitsu Pharmaceutical Co., Inc. Derives de piperidine
TW340842B (en) * 1995-08-24 1998-09-21 Pfizer Substituted benzylaminopiperidine compounds
TW458774B (en) * 1995-10-20 2001-10-11 Pfizer Antiemetic pharmaceutical compositions
US6329396B1 (en) 1996-06-10 2001-12-11 Pfizer Inc. Substituted benzylaminopiperidine compounds
GB9708484D0 (en) * 1997-04-25 1997-06-18 Merck Sharp & Dohme Therapeutic agents
US6214846B1 (en) * 1997-06-27 2001-04-10 Merck Sharp & Dohme Limited Substituted 3-(benzylamino)piperidine derivatives and their use as therapeutic agents
AU1409100A (en) * 1998-11-27 2000-06-19 Takeda Chemical Industries Ltd. Drugs
NZ501211A (en) * 1999-01-29 2001-10-26 Pfizer Prod Inc Pharmaceutical composition comprising macrolide antibiotic like erythromycin and a Substance P antagonist, and method for treating cancer, bacterial and protozoal infection in non-humans
US6255320B1 (en) * 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6262067B1 (en) * 1999-06-22 2001-07-17 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo 2,2,2 OCT-3-yl amine dihydrochloride and their pharmaceutical compositions
IL142810A0 (en) * 2000-05-03 2002-03-10 Pfizer Prod Inc Pharmaceutical uses for fluoroalkoxybenzylamino derivatives of nitrogen containing heterocycles
SK252004A3 (sk) * 2001-07-20 2005-03-04 Pfizer Products Inc. Použitie antagonistov receptora NK-1 na výrobu liečiva na liečenie abnormálneho úzkostného správania domácich zvierat a spôsob screeningu skúšanej zlúčeniny s cieľom stanoviť anxiolytickú účinnosť u psov
KR100834232B1 (ko) * 2004-01-30 2008-05-30 화이자 프로덕츠 인크. 액체 투여형용 베타-시클로덱스트린을 사용하는 다수회투여 제형을 얻기 위한 항균 방부제
BRPI0507325A (pt) * 2004-01-30 2007-07-03 Pfizer Prod Inc antagonistas dos receptores nk-1 para melhorar a recuperação da anestesia
KR100812046B1 (ko) * 2004-02-02 2008-03-10 화이자 프로덕츠 인크. 1-(2ｓ,3ｓ)-2-벤즈히드릴-ｎ-(5-삼급-부틸-2-메톡시벤질)퀴누클리딘-3-아민의 제조 방법
WO2014197137A1 (en) * 2013-04-29 2014-12-11 Howard Brooks-Korn Diversion-resistant formulation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8527052D0 (en) * 1985-11-02 1985-12-04 Beecham Group Plc Compounds
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
US5232929A (en) * 1990-11-28 1993-08-03 Pfizer Inc. 3-aminopiperidine derivatives and related nitrogen containing heterocycles and pharmaceutical compositions and use
ATE113947T1 (de) * 1990-06-01 1994-11-15 Pfizer 3-amino-2-arylchinuclidine, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische zubereitungen.
CA2086434C (en) * 1990-07-23 1998-09-22 John A. Lowe, Iii Quinuclidine derivatives
CZ387492A3 (en) * 1990-09-28 1994-02-16 Pfizer Analogs of non-aromatic hetero cycles containing nitrogen with a condensed ring, process of their preparation and use
WO1992012151A1 (en) * 1991-01-10 1992-07-23 Pfizer Inc. N-alkyl quinuclidinium salts as substance p antagonists
EP0573522B1 (de) * 1991-03-01 1994-12-14 Pfizer Inc. 1-azabicyclo[3.2.2]nonan-3-aminderivate
CA2106200C (en) * 1991-03-26 1996-11-19 Terry J. Rosen Stereoselective preparation of substituted piperidines
UA26401C2 (uk) * 1991-05-22 1999-08-30 Пфайзер Інк. Заміщеhі 3-аміhохіhуклідиhи
AU657552B2 (en) * 1991-05-31 1995-03-16 Pfizer Inc. Quinuclidine as substance P antagonists
JPH07110850B2 (ja) * 1991-06-20 1995-11-29 フアイザー・インコーポレイテツド 窒素含有複素環化合物のフルオロアルコキシベンジルアミノ誘導体
TW202432B (de) * 1991-06-21 1993-03-21 Pfizer
EP0533280B2 (de) * 1991-09-20 2004-12-01 Glaxo Group Limited Neue medizinische Indikation für Tachykinin-Antagonisten
HU9400728D0 (en) * 1991-09-26 1994-06-28 Pfizer Fused tricyclic nitrogen containing heterocycles as substance p receptor antagonists
JP2614408B2 (ja) * 1991-11-12 1997-05-28 ファイザー・インコーポレーテッド サブスタンスｐ受容体アンタゴニストとしての非環式エチレンジアミン誘導体
JP2656702B2 (ja) * 1992-03-23 1997-09-24 ファイザー製薬株式会社 ペプチド性キヌクリジン
DE69331190T2 (de) * 1992-05-18 2002-04-18 Pfizer Überbrückte azabicyclische derivate als substanz p antagonisten
ES2147759T3 (es) * 1992-12-10 2000-10-01 Pfizer Heterociclos no aromaticos sustituidos con aminometileno y uso como antagonistas de la sustancia p.
ATE166650T1 (de) * 1993-03-04 1998-06-15 Pfizer Spiroazacyclischderivate als substanz p antagonisten
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
WO2000010073A1 (en) * 1998-08-14 2000-02-24 Via, Inc. Mobile robotic snake

Also Published As

Publication number Publication date
DE69429208D1 (de) 2002-01-10
CN1100535C (zh) 2003-02-05
AU666077B2 (en) 1996-01-25
HU222243B1 (hu) 2003-05-28
EP0627221A2 (de) 1994-12-07
EP0627221B1 (de) 2001-11-28
DE69429208T2 (de) 2002-05-23
DK0627221T3 (da) 2002-02-11
KR950000144A (ko) 1995-01-03
NZ260674A (en) 2000-07-28
CN1121806A (zh) 1996-05-08
IL109802A0 (en) 1994-08-26
PT627221E (pt) 2002-04-29
TW318791B (de) 1997-11-01
JPH0753362A (ja) 1995-02-28
MY115310A (en) 2003-05-31
US5393762A (en) 1995-02-28
KR100190729B1 (ko) 1999-06-01
HUT71550A (en) 1995-12-28
EP0627221A3 (de) 1995-08-02
ZA943896B (en) 1995-12-04
RU94020410A (ru) 1996-05-10
CA2124990C (en) 1999-04-20
RU2135179C1 (ru) 1999-08-27
IL109802A (en) 2002-04-21
HU9401676D0 (en) 1994-09-28
AU6452194A (en) 1994-12-15
ES2164088T3 (es) 2002-02-16
JP2671972B2 (ja) 1997-11-05

Similar Documents

Publication Publication Date Title
ATE209490T1 (de) Substanz p antagonisten zur behandlung von erbrechen
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
DE69429299D1 (de) Verwendung von Tachykinin-Antagonisten zur Behandlung von Erbrechen
GB9406857D0 (en) Improvements in or relating to organic compounds
DK0701546T3 (da) Aromatiske acetylchlolinesteraseinhibitorer
ES2104358T3 (es) Inhibidores sililados de acetilcolinesterasa.
ATE212548T1 (de) Behandlung und prophylaxe von pankreatitis
DE69412178D1 (de) Apparat zur Behandlung von Lagen
DE59410340D1 (de) Verwendung von Bradykinin-Antagonisten zur Behandlung von Viruserkrankungen
ATE178336T1 (de) Verwendung einer therapeutischen zusammensetzung zur behandlung von bronchitis

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee